Dupixent® (dupilumab) Long-term Data Show Sustained Improvement in Lung Function and Reduction in Severe Exacerbations in Adults and Adolescents with Moderate-to-severe Asthma

TARRYTOWN, N.Y. and PARIS, Sept. 8, 2020 /PRNewswire/ -- With more than 2,200 patients enrolled, Phase 3 open-label extension trial is the largest of a biologic medicine ever conducted in asthma Data up to three years to be presented at the 2020 ERS International Congress also show a...

from PR Newswire: https://ift.tt/2RaWF1X